====================001====================
NA

CTRI/2009/091/000527

20July2014

Aclinicaltrialtostudythesafetyandefficacyof2mgand4mgofZYH1comparedtoPioglitazone45mgindyslipidemiawithtype2diabetesmellitus.
ProspectiveRandomisedEfficacyandSafetyofSaroglitazar(PRESSV).

Amulti-centric,randomized,doubleblindstudytoevaluatethesafetyandefficacyof2mgand4mgofZYH1comparedtoPioglitazone45mgindyslipidemiawithtype2diabetesmellitus.-ZYH1.08.001.01.1PROT

CadilaHealthcareLimited

09-09-2009

CTRI

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=732

NotRecruiting

No

27-07-2009122InterventionalRandomized,ParallelGroup,PlaceboControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Pre-numberedorcodedidenticalContainersBlindingandmasking:Participant,InvestigatorandOutcomeAssessorBlindedIndiaDrRHJaniZydusCadilaHousePlotno.360,TPS5,Serviceroad,VileParle(East)rhjani@zyduscadila.com91-22-26186057CadilaHealthcraeLimitedIntervention1:ZYH1:2mgor4mgoncedaily(OD)Oral&lt;br&gt;&lt;br&gt;ControlIntervention1:Pioglitazone:45mgOD&lt;br&gt;Oral&lt;br&gt;&lt;br&gt;PrimaryEfficacy&lt;br&gt;TG&lt;br&gt;Timepoint:Timeframe12and24weeks&lt;br&gt;SecondaryEfficacy:&lt;br&gt;LDL,VLDL,HDL,Totalcholesterol,Apo(a),ApoB,HbA1c,Fastingplasmaglucose(FPG),C-peptidetestandfastinginsulinforHOMAbetaandHOMAIR,&lt;br&gt;hs-CRP,Postprandialtriglyceride(PPTG)atselectedcentres&lt;br&gt;Timepoint:Timeframe12and24weeks&lt;br&gt;ZYH1.08.001.01.1.PROT+1AmendmentCadilaHealthcareLimited

27-07-2009

122

Interventional

Randomized,ParallelGroup,PlaceboControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Pre-numberedorcodedidenticalContainersBlindingandmasking:Participant,InvestigatorandOutcomeAssessorBlinded

NA

NA

NA

Intervention1:ZYH1:2mgor4mgoncedaily(OD)Oral&lt;br&gt;&lt;br&gt;ControlIntervention1:Pioglitazone:45mgOD&lt;br&gt;Oral&lt;br&gt;&lt;br&gt;

PrimaryEfficacy&lt;br&gt;TG&lt;br&gt;Timepoint:Timeframe12and24weeks&lt;br&gt;

ZYH1.08.001.01.1.PROT+1Amendment

====================002====================
NA

CTRI/2009/091/000533

20July2014

Aclinicaltrialtostudythesafetyandefficacyof2mgand4mgofZYH1comparedtoplaceboinhypertriglyceridemiawithtypeIIdiabetesnotcontrolledwithAtorvastatintherapy.[ProspectiveRandomisedEfficacyandSafetyofSaroglitazar(PRESSVI)].

Amulti-centric,prospective,randomized,doubleblindstudytoevaluatethesafetyandefficacyof2mgand4mgofZYH1comparedtoplaceboinhypertriglyceridemiawithtypeIIdiabetesnotcontrolledwithAtorvastatintherapy.

CadilaHealthcareLimited

28-08-2009

CTRI

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=736

NotRecruiting

No

10-08-2009300InterventionalRandomized,ParallelGroup,PlaceboControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Pre-numberedorcodedidenticalContainersBlindingandmasking:ParticipantandInvestigatorBlindedIndia;IndiaDrRHJaniZydusCadilaHouse
Plotno.360,TPS5,Serviceroad,VileParle(East)rhjani@zyduscadila.com91-22-26186057CadilaHealthcareLimitedIntervention1:ZYH12mg&amp;amp;4mg:onceorallyinthemorningbeforebreakfast,for12weeks.&lt;br&gt;ControlIntervention1:Placebo:onceorallyinthemorningbeforebreakfast,for12weeks.&lt;br&gt;PrimaryEfficacy:TG&lt;br&gt;Timepoint:Timeframe6and12weeks&lt;br&gt;SecondaryEfficacy:1)LDL,2)VLDL,3)HDL,4)Totalcholesterol,5)NonHDL-C,6)Apo(a),7)ApoB,8)hs-CRP&lt;br&gt;Timepoint:Timeframe6and12weeks&lt;br&gt;ZYH1.09.002.01.1.PROT+1AmendmentCadilaHealthcareLimited

10-08-2009

300

Interventional

Randomized,ParallelGroup,PlaceboControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Pre-numberedorcodedidenticalContainersBlindingandmasking:ParticipantandInvestigatorBlinded

NA

NA

NA

Intervention1:ZYH12mg&amp;amp;4mg:onceorallyinthemorningbeforebreakfast,for12weeks.&lt;br&gt;ControlIntervention1:Placebo:onceorallyinthemorningbeforebreakfast,for12weeks.&lt;br&gt;

PrimaryEfficacy:TG&lt;br&gt;Timepoint:Timeframe6and12weeks&lt;br&gt;

ZYH1.09.002.01.1.PROT+1Amendment

====================003====================
NA

CTRI/2010/091/000107

20July2014

AclinicaltrialtostudytheeffectsofZYH1inpatientswithhightriglyceridelevelsinHIVassociatedlipodystrophy..[ProspectiveRandomisedEfficacyandSafetyofSaroglitazar(PRESSVII)].

Aprospective,multi-centric,open-label,singlearmstudytoevaluatethesafetyandefficacyof4mgofZYH1inhypertriglyceridemiainHIVassociatedlipodystrophy-NA

CadilaHealthcareLimited

09-09-2010

CTRI

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1322

NotRecruiting

No

21-08-201050InterventionalSingleArmTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:NotApplicableMethodofallocationconcealment:Pre-numberedorcodedidenticalContainersBlindingandmasking:OpenLabelIndiaDrRHJaniZydusCadilaHouse,2ndFloorPlotNo.360,TPS5,Serviceroad,VileParle(East)rhjani@zyduscadila.com91-22-26186052CadilaHealthcareLimitedIntervention1:ZYH1:Dose-4mg&lt;br&gt;Frequency-Oncedaily&lt;br&gt;Route-Oral&lt;br&gt;ControlIntervention1:NA:NA&lt;br&gt;TriglyceridesTimepoint:At6weeksand12weeksLowdensitylipoprotein(LDL),&lt;br/&gt;&lt;br&gt;Verylowdensitylipoprotein(VLDL)Highdensitylipoprotein(HDL)&lt;br/&gt;&lt;br&gt;Totalcholesterol&lt;br/&gt;&lt;br&gt;NonHDLCholesterol(Measuredvalue)Apo(a)&amp;ApoB&lt;br/&gt;&lt;br&gt;FastinginsulinandC-peptideforHOMAbetaandIR.Timepoint:At6weeksand12weeksZYH1.09.003.01.PROT,Version1.0dated09/03/2009CadilaHealthcareLimited

21-08-2010

50

Interventional

SingleArmTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:NotApplicableMethodofallocationconcealment:Pre-numberedorcodedidenticalContainersBlindingandmasking:OpenLabel

NA

NA

NA

Intervention1:ZYH1:Dose-4mg&lt;br&gt;Frequency-Oncedaily&lt;br&gt;Route-Oral&lt;br&gt;ControlIntervention1:NA:NA&lt;br&gt;

TriglyceridesTimepoint:At6weeksand12weeks

ZYH1.09.003.01.PROT,Version1.0dated09/03/2009

====================004====================
NA

CTRI/2010/091/000108

20July2014

Aclinicaltrialtostudytheeffectsof4mgZYH1inpatientswithNonalcoholicsteatohepatitis(NASH)..[ProspectiveRandomisedEfficacyandSafetyofSaroglitazar(PRESSVIII)].

Aprospective,multi-centric,open-label,singlearmstudytoevaluatethesafetyandefficacyof4mgofZYH1inNon-alcoholicsteatohepatitis(NASH).-NA

CadilaHealthcareLimited

22-07-2010

CTRI

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1323

NotRecruiting

No

26-07-201030InterventionalSingleArmTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Pre-numberedorcodedidenticalContainersBlindingandmasking:OpenLabelIndiaDrRHJaniPlotNo.360,TPS5,ServiceRoad,VileParle(East).rhjani@zyduscadila.com26186057CadilaHealthcareLimitedIntervention1:ZYH1:Dose-4mg&lt;br&gt;Frequency-oncedaily(OD),&lt;br&gt;Route-Oral&lt;br&gt;ControlIntervention1:NIL:NIL&lt;br&gt;PercentagedecreaseinALTfrombaselineTimepoint:at6weeksand12weeksC-peptidetestforHOMAbetaandHOMAIR&lt;br&gt;Timepoint:at6weeksand12weeks;SustainedreductioninALTlevel.Timepoint:at6weeksand12weeks;TriglycerideTimepoint:at6weeksand12weeksZYH1.09.004.01.PROT,Version1.0,dated20/03/2009CadilaHealthcareLimited

26-07-2010

30

Interventional

SingleArmTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Pre-numberedorcodedidenticalContainersBlindingandmasking:OpenLabel

NA

NA

NA

Intervention1:ZYH1:Dose-4mg&lt;br&gt;Frequency-oncedaily(OD),&lt;br&gt;Route-Oral&lt;br&gt;ControlIntervention1:NIL:NIL&lt;br&gt;

PercentagedecreaseinALTfrombaselineTimepoint:at6weeksand12weeks

ZYH1.09.004.01.PROT,Version1.0,dated20/03/2009

====================005====================
NA

CTRI/2010/091/000164

20July2014

AclinicaltrialtostudytheeffectsofZYH1andFenofibrateinpatientswithhighlipidlevels.(ProspectiveRandomisedEfficacyandSafetyofSaroglitazar(PRESSI).

A12week,randomized,doubleblindparallelgroupprospectivedoserangingstudyofZYH1withanopenfenofibratearmtoevaluatetheefficacyondyslipidemiainpatientswithoutdiabetes.-NA

CadilaHealthcareLimited

09-03-2010

CTRI

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1377

NotRecruiting

No

08-08-200660InterventionalRandomized,ParallelGroup,ActiveControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:On-sitecomputersystemBlindingandmasking:ParticipantandInvestigatorBlindedIndiaDrRHJaniCadilaHealthcarelimited,ZydusCadilaHousePlotNo.360,TPS5,ServiceRoad,VileParle(East)rhjani@zyduscadila.com91-22-26186052CadilaHealthcareLimitedIntervention1:ZYH10.5mg,1mg,2mgand4mg:onetabletoncedailyofeither0.5mg,1mg,2mgor4mginthemorningfortheentiredurationofthestudyi.e.for12weeks.&lt;br&gt;ControlIntervention1:Fenofibrate160mg:Frequency-oncedaily&lt;br&gt;Dosage-160mg&lt;br&gt;Route-Oral&lt;br&gt;Primaryefficacyendpoints:1.Triglyceride2.LowdensityLipoproteins(LDL)cholesterol,3.Verylowdensitylipoprotein(VLDL)cholesterol,4.HDLcholesteroland5.FastingGlucose.Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)Secondaryefficacyendpoints:&lt;br/&gt;&lt;br&gt;1.HbA1C,&lt;br/&gt;&lt;br&gt;2.Insulinand&lt;br/&gt;&lt;br&gt;3.C-Reactiveprotein(CRP)&lt;br/&gt;&lt;br&gt;Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)2001Ver.01CadilaHealthcareLimited

08-08-2006

60

Interventional

Randomized,ParallelGroup,ActiveControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:On-sitecomputersystemBlindingandmasking:ParticipantandInvestigatorBlinded

NA

NA

NA

Intervention1:ZYH10.5mg,1mg,2mgand4mg:onetabletoncedailyofeither0.5mg,1mg,2mgor4mginthemorningfortheentiredurationofthestudyi.e.for12weeks.&lt;br&gt;ControlIntervention1:Fenofibrate160mg:Frequency-oncedaily&lt;br&gt;Dosage-160mg&lt;br&gt;Route-Oral&lt;br&gt;

Primaryefficacyendpoints:1.Triglyceride2.LowdensityLipoproteins(LDL)cholesterol,3.Verylowdensitylipoprotein(VLDL)cholesterol,4.HDLcholesteroland5.FastingGlucose.Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)

2001Ver.01

====================006====================
NA

CTRI/2010/091/000165

20July2014

Aclinicaltrialtostudytheeffectsoftwodrugs,ZYH1andRosiglitazoneindiabeticpatientswithhighlipidlevels.[ProspectiveRandomisedEfficacyandSafetyofSaroglitazar(PRESSII)]

A12week,randomised,doubleblindparallelgroupprospectivedoserangingstudyofZYH1withanopenRosiglitazonearmtoevaluatetheefficacyondyslipidemiainpatientswithdiabetes-NA

CadilaHealthcareLimited

09-03-2010

CTRI

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1378

NotRecruiting

No

02-11-200630InterventionalRandomized,ParallelGroup,ActiveControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Sequentiallynumbered,sealed,opaqueenvelopesBlindingandmasking:ParticipantandInvestigatorBlindedIndiaDrRHJaniZydusCadilaHousePlotNo.360,TPS5,ServiceRoad,VileParle(East)rhjani@zyduscadila.com91-22-26186052CadilaHealthcareLimitedIntervention1:ZYH10.5mg,1mg,2mgand4mg:onetabletoncedailyofeither0.5mg,1mg,2mgor4mginthemorningfortheentiredurationofthestudyi.e.for12weeks&lt;br&gt;ControlIntervention1:Rosiglitazone8/16mg:onetabletoncedailyinthemorningfortheentiredurationofthestudyi.e.for12weeks&lt;br&gt;Primaryefficacyendpoints:1.Triglyceride2.LowdensityLipoproteins(LDL)cholesterol,3.Verylowdensitylipoprotein(VLDL)cholesterol,4.HDLcholesteroland5.FastingGlucose.Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)Secondaryefficacyendpoints:1.HbA1C,2.Insulinand3.C-Reactiveprotein(CRP)Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)2002Ver.01CadilaHealthcareLimited

02-11-2006

30

Interventional

Randomized,ParallelGroup,ActiveControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Sequentiallynumbered,sealed,opaqueenvelopesBlindingandmasking:ParticipantandInvestigatorBlinded

NA

NA

NA

Intervention1:ZYH10.5mg,1mg,2mgand4mg:onetabletoncedailyofeither0.5mg,1mg,2mgor4mginthemorningfortheentiredurationofthestudyi.e.for12weeks&lt;br&gt;ControlIntervention1:Rosiglitazone8/16mg:onetabletoncedailyinthemorningfortheentiredurationofthestudyi.e.for12weeks&lt;br&gt;

Primaryefficacyendpoints:1.Triglyceride2.LowdensityLipoproteins(LDL)cholesterol,3.Verylowdensitylipoprotein(VLDL)cholesterol,4.HDLcholesteroland5.FastingGlucose.Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)

2002Ver.01

====================007====================
NA

CTRI/2010/091/000166

20July2014

Aclinicaltrialtostudytheeffectsoftwodrugs,ZYH1andPioglitazoneindiabeticpatientswithhighlipidlevels.[ProspectiveRandomisedEfficacyandSafetyofSaroglitazar(PRESSIII)].

A12week,randomised,doubleblindparallelgroupprospectivedoserangingstudyofZYH1withanopenPioglitazonearmtoevaluatetheefficacyondyslipidemiainpatientswithdiabetes.-NA

CadilaHealthcareLimited

09-03-2010

CTRI

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1379

NotRecruiting

No

17-11-200660InterventionalRandomized,ParallelGroup,ActiveControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Sequentiallynumbered,sealed,opaqueenvelopesBlindingandmasking:ParticipantandInvestigatorBlindedIndiaDrRHJaniCadilaHealthcareLimited,ZydusCadilaHousePlotNo.360,TPS5,ServiceRoad,VileParle(East)rhjani@zyduscadila.com91-22-26186052CadilaHealthcareLimitedIntervention1:ZYH10.5mg,1mg,2mgand4mg:onetabletoncedailyofeither0.5mg,1mg,2mgor4mginthemorningfortheentiredurationofthestudyi.e.for12weeks.&lt;br&gt;ControlIntervention1:Pioglitazone(45mgdaily):onetabletoncedailyinthemorningfortheentiredurationofthestudyi.e.for12weeks&lt;br&gt;Primaryefficacyendpoints:1.Triglyceride2.LowdensityLipoproteins(LDL)cholesterol,3.Verylowdensitylipoprotein(VLDL)cholesterol,4.HDLcholesteroland5.FastingGlucose.Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)Secondaryefficacyendpoints:1.HbA1C,2.Insulinand3.C-Reactiveprotein(CRP)Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)2003Ver.02CadilaHealthcareLimited

17-11-2006

60

Interventional

Randomized,ParallelGroup,ActiveControlledTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:ComputergeneratedrandomizationMethodofallocationconcealment:Sequentiallynumbered,sealed,opaqueenvelopesBlindingandmasking:ParticipantandInvestigatorBlinded

NA

NA

NA

Intervention1:ZYH10.5mg,1mg,2mgand4mg:onetabletoncedailyofeither0.5mg,1mg,2mgor4mginthemorningfortheentiredurationofthestudyi.e.for12weeks.&lt;br&gt;ControlIntervention1:Pioglitazone(45mgdaily):onetabletoncedailyinthemorningfortheentiredurationofthestudyi.e.for12weeks&lt;br&gt;

Primaryefficacyendpoints:1.Triglyceride2.LowdensityLipoproteins(LDL)cholesterol,3.Verylowdensitylipoprotein(VLDL)cholesterol,4.HDLcholesteroland5.FastingGlucose.Timepoint:Frombaseline,visit2(Week0)tovisit8(Week12)

2003Ver.02

====================008====================
NA

CTRI/2013/06/003754

20July2014

AphaseIVclinicalstudytoevaluatethesafetyandefficacyofSaroglitazar(ZYH1)ascomparedtofenofibrateinpatientswithdyslipidemia.[ProspectiveRandomisedEfficacyandSafetyofSaroglitazar(PRESSX)].

_??Amulticentric,prospective,randomized,openlabelPhaseIVclinicalstudytoevaluatethesafetyandefficacyofSaroglitazar(ZYH1)ascomparedtofenofibrateinpatientswithdyslipidemia._??-NA

CadilaHealthcareLimited

14-06-2013

CTRI

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=6705

Recruiting

No

20-08-20131010InterventionalRandomized,ParallelGroup,MultipleArmTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:NotApplicableMethodofallocationconcealment:NotApplicableBlindingandmasking:OpenLabelIndiaDrRHJaniZydusCadilaHousePlotNo.360,TPS5,ServiceRoad,VileParle(E)MumbaiMAHARASHTRA400057Indiarhjani@zyduscadila.com26186052CadilaHealthcareLimitedIntervention1:Fenofibrate:Route-OralFrequency-OncedailyDuration-06MonthsDosage:-Fenofibrate160Mg&lt;br&gt;ControlIntervention1:Saroglitazar2Mgand4Mg:Route-Oral&lt;br&gt;Frequency-Oncedaily&lt;br&gt;Duration-06Months&lt;br&gt;Dosage:-Saroglitazar2Mg0r4Mg&lt;br&gt;Tocomparethepercentagechangeintriglyceride(TG)levelsin2and4mgofSaroglitazarascomparedtofenofibrateTimepoint:6weeks,12weeksand24weeks1.Tocomparethepercentagechangeinlipidparameters&lt;br/&gt;&lt;br&gt;a.LDL,&lt;br/&gt;&lt;br&gt;b.VLDL,&lt;br/&gt;&lt;br&gt;c.HDL-C,&lt;br/&gt;&lt;br&gt;d.Totalcholesterol&lt;br/&gt;&lt;br&gt;e.NonHDLcholesterol,&lt;br/&gt;&lt;br&gt;f.ApoA1&lt;br/&gt;&lt;br&gt;g.ApoB.&lt;br/&gt;&lt;br&gt;2.Tocomparethepercentagechangeinhs-CRP,aninflammatorymarkerofatherosclerosisTimepoint:6weeks,12weeksand24weeksZYH1.12.001.01.PROT,Version1.0,Date8Nov2012NA

20-08-2013

1010

Interventional

Randomized,ParallelGroup,MultipleArmTrial&lt;br&gt;Methodofgeneratingrandomizationsequence:NotApplicableMethodofallocationconcealment:NotApplicableBlindingandmasking:OpenLabel

NA

NA

NA

Intervention1:Fenofibrate:Route-OralFrequency-OncedailyDuration-06MonthsDosage:-Fenofibrate160Mg&lt;br&gt;ControlIntervention1:Saroglitazar2Mgand4Mg:Route-Oral&lt;br&gt;Frequency-Oncedaily&lt;br&gt;Duration-06Months&lt;br&gt;Dosage:-Saroglitazar2Mg0r4Mg&lt;br&gt;

Tocomparethepercentagechangeintriglyceride(TG)levelsin2and4mgofSaroglitazarascomparedtofenofibrateTimepoint:6weeks,12weeksand24weeks

ZYH1.12.001.01.PROT,Version1.0,Date8Nov2012

